Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experienceTransition further highlights transformation of the Board to lead ...
Context doses first patient in Phase 1 clinical trial evaluating CTIM-76
Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or ...
Morningstar4d
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026. “Dosing of the first patient in the CTIM-76 Phase 1 trial represents a key advancement of ...
Nasdaq3d
Context Therapeutics Doses First Patient in Phase 1 Trial of CTIM-76 for CLDN6-Positive Cancers
Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the ...
Stockhouse3d
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026. “Dosing of the first patient in the CTIM-76 Phase 1 trial represents a key advancement of our ...
Context Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap ...